EA201071126A1 - Антагонисты рецепторов глюкагона - Google Patents

Антагонисты рецепторов глюкагона

Info

Publication number
EA201071126A1
EA201071126A1 EA201071126A EA201071126A EA201071126A1 EA 201071126 A1 EA201071126 A1 EA 201071126A1 EA 201071126 A EA201071126 A EA 201071126A EA 201071126 A EA201071126 A EA 201071126A EA 201071126 A1 EA201071126 A1 EA 201071126A1
Authority
EA
Eurasian Patent Office
Prior art keywords
glucagon
receptor antagonists
glucagon receptor
receptor
inhibit
Prior art date
Application number
EA201071126A
Other languages
English (en)
Inventor
Рон Ли Джуниор Милликан
Эндрю Игорь Коритко
Брайан Джон Ондек
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40794248&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201071126(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201071126A1 publication Critical patent/EA201071126A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Настоящее изобретение относится к полипептидам-антагонистам рецепторов глюкагона, которые ингибируют связывание гормона глюкагона с рецептором к нему. Более конкретно, настоящее изобретение относится к высокоаффинным антителам к рецептору глюкагона или фрагменту Fab таких антител, которые ингибируют связывание гормона глюкагона с рецептором к нему, и к их применению в лечении и профилактике диабета 2 типа (ИНСД) и сходных заболеваний у млекопитающих.
EA201071126A 2008-03-27 2009-03-17 Антагонисты рецепторов глюкагона EA201071126A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3990708P 2008-03-27 2008-03-27
PCT/US2009/037349 WO2009120530A1 (en) 2008-03-27 2009-03-17 Glucagon receptor antagonists

Publications (1)

Publication Number Publication Date
EA201071126A1 true EA201071126A1 (ru) 2011-04-29

Family

ID=40794248

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201071126A EA201071126A1 (ru) 2008-03-27 2009-03-17 Антагонисты рецепторов глюкагона

Country Status (15)

Country Link
US (2) US7968686B2 (ru)
EP (1) EP2268670A1 (ru)
JP (1) JP5438095B2 (ru)
KR (1) KR101235934B1 (ru)
CN (1) CN101983208A (ru)
AR (1) AR070844A1 (ru)
AU (1) AU2009228866A1 (ru)
BR (1) BRPI0910118A2 (ru)
CA (1) CA2719761A1 (ru)
CL (1) CL2009000586A1 (ru)
EA (1) EA201071126A1 (ru)
MX (1) MX2010010517A (ru)
PE (1) PE20091674A1 (ru)
TW (1) TW201000126A (ru)
WO (1) WO2009120530A1 (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102482350B (zh) * 2009-09-08 2015-08-05 株式会社新药 作用于胰高血糖素受体的抗体及其应用
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
US9217040B2 (en) 2011-01-14 2015-12-22 The Regents Of The University Of California Therapeutic antibodies against ROR-1 protein and methods for use of same
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013059531A1 (en) * 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
EP2785740A1 (en) 2011-12-02 2014-10-08 Eli Lilly and Company Anti-glucagon antibodies and uses thereof
SG11201508264UA (en) * 2013-05-07 2015-11-27 Rinat Neuroscience Corp Anti-glucagon receptor antibodies and methods of use thereof
CA2950695C (en) * 2014-06-08 2022-12-06 REMD Biotherapeutics, Inc Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies
WO2018044903A1 (en) 2016-08-30 2018-03-08 Regeneron Pharmaceuticals, Inc. Methods of treating severe insulin resistance by interfering with glucagon receptor signaling
US20190248888A1 (en) 2016-10-20 2019-08-15 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
MX2019008722A (es) 2017-01-27 2019-10-02 Ngm Biopharmaceuticals Inc Proteínas de unión al receptor de glucagón y métodos para usarlas.
US20210130480A1 (en) 2017-08-22 2021-05-06 Regeneron Pharmaceuticals, Inc. Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
CN110357959B (zh) 2018-04-10 2023-02-28 鸿运华宁（杭州）生物医药有限公司 Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
US10961315B2 (en) 2018-07-27 2021-03-30 Ngm Biopharmaceuticals, Inc. Method of treating type I diabetes by administering a combination of a glucagon receptor antagonist and an anti-CD3 antibody
CN112996811B (zh) 2018-12-21 2022-11-22 江苏恒瑞医药股份有限公司 双特异性蛋白

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776725A (en) 1992-08-28 1998-07-07 Zymogenetics, Inc. Recombinant production of glucagon receptors
CA2142819C (en) 1992-08-28 2003-08-19 Wayne R. Kindsvogel Glucagon receptors
AU2002239538A1 (en) 2000-12-06 2002-06-18 Deltagen, Inc. Transgenic mice containing glucagon receptor gene disruptions
AR036711A1 (es) * 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
US7399853B2 (en) 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
WO2006005469A2 (en) 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
CN101484081A (zh) 2006-07-04 2009-07-15 布拉科成像S.P.A.公司 生物组织尤其是肿瘤组织等的局部热切除装置
CL2007002668A1 (es) 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.

Also Published As

Publication number Publication date
KR101235934B1 (ko) 2013-02-21
CA2719761A1 (en) 2009-10-01
AR070844A1 (es) 2010-05-05
US20110212092A1 (en) 2011-09-01
AU2009228866A1 (en) 2009-10-01
MX2010010517A (es) 2010-12-20
TW201000126A (en) 2010-01-01
US7968686B2 (en) 2011-06-28
US20090252727A1 (en) 2009-10-08
EP2268670A1 (en) 2011-01-05
JP2011518125A (ja) 2011-06-23
WO2009120530A1 (en) 2009-10-01
JP5438095B2 (ja) 2014-03-12
PE20091674A1 (es) 2009-11-04
KR20100117130A (ko) 2010-11-02
BRPI0910118A2 (pt) 2015-12-29
CL2009000586A1 (es) 2010-06-04
CN101983208A (zh) 2011-03-02

Similar Documents

Publication Publication Date Title
EA201071126A1 (ru) Антагонисты рецепторов глюкагона
NL301089I2 (nl) imlifidase
PH12019502356A1 (en) Trem2 antigen binding proteins and uses thereof
MA32982B1 (fr) Proteines de liaison au recepteur cgrp humain
EA201100546A1 (ru) Полипептиды, вариабельные домены антител и антагонисты
MX2009003093A (es) Composiciones y metodos relacionados con anticuerpos del receptor de glucagon.
PE20091193A1 (es) Proteinas humanas de union a antigenos del gm-csf
UA102867C2 (ru) Антитела к cxcr4 и их применение в лечении рака
WO2006052723A3 (en) G protein coupled receptor agonists and antagonists and methods of use
MX2009008104A (es) Hepcidina, antagonistas de hepcidina y metodos de uso.
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.
IL183165A (en) Polypeptides derived from the extracellular protein of the trem-1 protein and which can be used as antagonists of the trem-1 protein, preparations containing them and their uses for the preparation of a drug for the treatment of sepsis, septic shock and sepsis-like conditions
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
GEP20115324B (en) Tweak binding antibodies
EA200870465A1 (ru) Антагонисты рецептора il-8
MA32980B1 (fr) Proteines de liaison a la myostatine
MX2007008017A (es) Polipeptidos que se ligan a br3 y usos de los mismos.
WO2012170438A3 (en) HUMAN ANTIGEN BINDING PROTEINS THAT BIND TO A COMPLEX COMPRISING β-KLOTHO AND AN FGF RECEPTOR
EA201291067A1 (ru) Гуманизированные антигенсвязывающие белки к миостатину
MX357972B (es) Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3.
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
IL194550A (en) Isolated antibodies or their fragments that bind to human protein tyrosine phosphate in a cell, their pharmaceutical preparations and their use
ATE538650T1 (de) Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht
AR070346A1 (es) Anticuerpo especifico del receptor de linfopoyetina estromal timica (tslpr) y usos en trastornos inflamatorios e inflamatorios alergicos